ATE369366T1 - S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers - Google Patents

S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers

Info

Publication number
ATE369366T1
ATE369366T1 AT05778749T AT05778749T ATE369366T1 AT E369366 T1 ATE369366 T1 AT E369366T1 AT 05778749 T AT05778749 T AT 05778749T AT 05778749 T AT05778749 T AT 05778749T AT E369366 T1 ATE369366 T1 AT E369366T1
Authority
AT
Austria
Prior art keywords
proton pump
pump inhibitor
monohydrate salt
sodium monohydrate
tenatoprazole sodium
Prior art date
Application number
AT05778749T
Other languages
English (en)
Inventor
Avraham Cohen
Francois Schutze
Suzy Charbit
Frederic Martinet
Herve Ficheux
Michel Homerin
Original Assignee
Sidem Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidem Pharma filed Critical Sidem Pharma
Application granted granted Critical
Publication of ATE369366T1 publication Critical patent/ATE369366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT05778749T 2004-06-17 2005-06-17 S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers ATE369366T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0406617A FR2871800B1 (fr) 2004-06-17 2004-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique

Publications (1)

Publication Number Publication Date
ATE369366T1 true ATE369366T1 (de) 2007-08-15

Family

ID=34948439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05778749T ATE369366T1 (de) 2004-06-17 2005-06-17 S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers

Country Status (23)

Country Link
US (1) US7402593B2 (de)
EP (1) EP1664044B1 (de)
JP (1) JP5393028B2 (de)
KR (1) KR101174932B1 (de)
CN (1) CN101001858B (de)
AT (1) ATE369366T1 (de)
AU (1) AU2005261580C1 (de)
BR (1) BRPI0512151A (de)
CA (1) CA2568993C (de)
CY (1) CY1106950T1 (de)
DE (1) DE602005001918T2 (de)
DK (1) DK1664044T3 (de)
ES (1) ES2290921T3 (de)
FR (1) FR2871800B1 (de)
HK (1) HK1106246A1 (de)
IL (1) IL179813A (de)
MX (1) MXPA06014849A (de)
NO (1) NO20070250L (de)
NZ (1) NZ551866A (de)
PL (1) PL1664044T3 (de)
PT (1) PT1664044E (de)
RU (1) RU2376304C2 (de)
WO (1) WO2006005853A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2909380B1 (fr) * 2006-12-04 2009-02-20 Sidem Pharma Sa Sa Conglomerats de sels de potassium de tenatoprazole
CN102276602A (zh) * 2011-06-30 2011-12-14 福建省福抗药业股份有限公司 一种泰妥拉唑盐的精制方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH07157430A (ja) * 1993-10-12 1995-06-20 Tokyo Tanabe Co Ltd 安定化された医薬組成物
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08239381A (ja) * 1995-03-02 1996-09-17 Toa Eiyoo Kk 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US7271182B2 (en) * 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
HUP0303144A3 (en) * 2001-02-02 2007-08-28 Teva Pharma Process for the production of substituted 2-(2-pyridylmethyl)sulfinyl-1h-benzimidazoles
CN1453278A (zh) * 2002-04-23 2003-11-05 中国人民解放军军事医学科学院放射医学研究所 一种拉唑类化合物及其制备方法与应用
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
BRPI0310118B1 (pt) * 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CA2512928A1 (en) * 2003-02-24 2004-09-02 Mitsubishi Pharma Corporation The enantiomer of tenatoprazole and the use thereof in therapy
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1608649A2 (de) * 2003-03-28 2005-12-28 Sidem Pharma SA Verfahren zur herstellung von enantioselektiven sulfoxid-derivaten

Also Published As

Publication number Publication date
WO2006005853A1 (fr) 2006-01-19
PT1664044E (pt) 2007-11-19
IL179813A (en) 2011-01-31
MXPA06014849A (es) 2007-03-23
AU2005261580C1 (en) 2011-06-16
RU2007101521A (ru) 2008-07-27
NZ551866A (en) 2010-07-30
AU2005261580B2 (en) 2011-02-03
JP2008502665A (ja) 2008-01-31
RU2376304C2 (ru) 2009-12-20
FR2871800A1 (fr) 2005-12-23
NO20070250L (no) 2007-03-14
KR101174932B1 (ko) 2012-08-20
DK1664044T3 (da) 2007-12-27
HK1106246A1 (en) 2008-03-07
CA2568993A1 (fr) 2006-01-19
CN101001858A (zh) 2007-07-18
CA2568993C (fr) 2013-12-17
JP5393028B2 (ja) 2014-01-22
FR2871800B1 (fr) 2006-08-25
EP1664044A1 (de) 2006-06-07
AU2005261580A1 (en) 2006-01-19
BRPI0512151A (pt) 2008-02-12
CN101001858B (zh) 2012-03-14
KR20070045194A (ko) 2007-05-02
DE602005001918D1 (de) 2007-09-20
EP1664044B1 (de) 2007-08-08
IL179813A0 (en) 2007-05-15
US7402593B2 (en) 2008-07-22
US20070179176A1 (en) 2007-08-02
ES2290921T3 (es) 2008-02-16
DE602005001918T2 (de) 2008-04-24
CY1106950T1 (el) 2012-09-26
PL1664044T3 (pl) 2007-12-31

Similar Documents

Publication Publication Date Title
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
ZA200707009B (en) Multimers of pyrimidinone derivatives and their use as human neutrophil elastate inhibitors
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
ATE444066T1 (de) Liganden für den cannabinoidrezeptoren
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA200802213A1 (ru) Способы лечения заболеваний крови
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA200802329A1 (ru) Производные триазола ii
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MX2007013624A (es) Inhibidores de proteina cinasa.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
GEP20115222B (en) New pharmaceutical compounds
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1664044

Country of ref document: EP